Raymond James Initiates Coverage On Third Harmonic Bio with Outperform Rating, Announces Price Target of $18
Portfolio Pulse from Benzinga Newsdesk
Raymond James has initiated coverage on Third Harmonic Bio (NASDAQ:THRD) with an Outperform rating and set a price target of $18.
June 07, 2024 | 9:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has initiated coverage on Third Harmonic Bio with an Outperform rating and set a price target of $18. This positive analyst rating could boost investor confidence and potentially drive the stock price up in the short term.
The initiation of coverage with an Outperform rating by a reputable analyst from Raymond James is likely to attract positive attention from investors. The price target of $18 suggests significant upside potential, which could lead to increased buying activity and a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100